This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
SEE YOU NEXT YEAR: May 7-10, 2023 | In-Person + Digital
San Diego, CA, USA

Troels Koch, PhD
Senior Vice President, Chemistry at MiNa Therapeutics


Daniel brings 15 years of industry experience to the team, with an emphasis on TIDES process R&D, manufacturing and CMC development. He leads Bachem’s oligonucleotide unit including innovation projects, R&D and manufacturing activities. Daniel holds a PhD in organic chemistry from the University of Konstanz, and an MBA from the International Institute for Management Development (IMD), Lausanne. In previous stages of his career he was a lab head for process optimization, technology transfer, Quality by Design, and scale-up of synthetic peptide manufacturing procedures. From 2012, Daniel was a Vice President API Manufacturing and had full responsibility for all large-scale solid phase peptide and oligonucleotide syntheses, downstream operations, and CMC activities within Bachem AG.

Agenda Sessions

  • Chairman’s Remarks: Case Studies of Preclinical and Clinical Oligonucleotides in Development

  • Chairman’s Remarks: Emerging Platforms for Oligonucleotides